Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
Single-cell proteomics
LF Vistain, S Tay - Trends in biochemical sciences, 2021 - cell.com
The inability to make broad, minimally biased measurements of a cell's proteome stands as
a major bottleneck for understanding how gene expression translates into cellular …
a major bottleneck for understanding how gene expression translates into cellular …
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
[HTML][HTML] Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity
Cytokine-inducible SH2-containing protein (CIS; encoded by the gene CISH) is a key
negative regulator of interleukin-15 (IL-15) signaling in natural killer (NK) cells. Here, we …
negative regulator of interleukin-15 (IL-15) signaling in natural killer (NK) cells. Here, we …
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
J Rossi, P Paczkowski, YW Shen… - Blood, The Journal …, 2018 - ashpublications.org
After treatment with chimeric antigen receptor (CAR) T cells, interleukin-15 (IL-15) elevation
and CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes …
and CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes …
NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors
Solid tumors are refractory to cellular immunotherapies in part because they contain
suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that …
suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that …
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in
treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients …
treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients …
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
KP Nishimoto, T Barca, A Azameera… - Clinical & …, 2022 - Wiley Online Library
Objectives Autologous chimeric antigen receptor (CAR) αβ T‐cell therapies have
demonstrated remarkable antitumor efficacy in patients with haematological malignancies; …
demonstrated remarkable antitumor efficacy in patients with haematological malignancies; …